Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich protein HaeIII subfamily 1 (PRH1) is a salivary glycoprotein encoded by the PRH1 gene, predominantly secreted by the parotid and submandibular/sublingual glands. The gene exhibits considerable polymorphism, with several allelic variants (e.g., PIF-s, Pa, Db-s) influencing protein structure and function. PRH1 is a component of the acquired pellicle on teeth, where it acts as a modulator of bacterial adhesion—particularly affecting Streptococcus mutans colonization—and as a potent inhibitor of calcium phosphate crystal growth, helping to protect dental enamel. Certain genetic variants of PRH1 are associated with increased susceptibility to dental caries. PRH1 is not a conventional therapeutic target (i.e., not an enzyme, receptor, or transporter) but is a biomolecule relevant to oral health and disease risk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline-rich protein HaeIII subfamily 1 (PRH1).